PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Alto Marketing Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Maybridge Fragments Selected by Nordlund Centre - Maybridge Ro3 500 Fragment Library to support establishment of new fragment screening-based drug discovery platform
Thermo Fisher Scientific Maybridge Fragments Selected by Nordlund Centre

 

NewswireToday - /newswire/ - Southampton, Hampshire, United Kingdom, 2010/03/11 - Maybridge Ro3 500 Fragment Library to support establishment of new fragment screening-based drug discovery platform.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific, the world leader in serving science, today announced that the Nordlund Centre for Biomedical Structural Biology at Nanyang Technological University in Singapore has purchased its Maybridge Ro3 500 Fragment Library. Nordlund will use this “off-the-shelf” set of 500 pharmacophorically-rich Maybridge compounds as a globally renowned benchmark fragment library to optimize structure-based screening methods for a diverse set of drug candidates. The ultimate objective of the project is to understand the optimal screening protocols for different protein target families and to publish these results for the scientific and drug discovery community.

The new Nordlund Centre, based in the prestigious Biopolis hub in Singapore, is headed by Professor Pär Nordlund, a renowned structural biologist and visiting professor from the Karolinska Institute in Stockholm. Through this comparative study, the Nordlund team will establish a platform for the efficient generation of chemical probes using fragment-based methods. The six- to nine-month study will guide researchers and the entire industry on the preferred fragment screening technique for several protein classes.

The study includes seven protein classes, including HsP90. The group will assess fragment binding in each protein class using a range of standard techniques, including ITC, NMR, SPR, DSF and X-ray crystallography.

“We selected the Maybridge Fragment library as a benchmark for our comparative study as it is a globally renowned and industry recognised set of diverse and high-quality compounds,” said Dr. Andreas Larsson, project leader within the Nordlund group. “Of particular interest to us was the validated aqueous solubility data provided by Maybridge scientists, where solubility checks up to five mMol in aqueous phosphate buffer have been measured.”

The Nordlund team features individuals from both academia and the pharmaceutical industry with a broad range of competencies. In addition to fragment-based lead generation, these competencies include: structural biology, high-throughput protein production and crystallography, membrane protein production and biophysical characterisation. Such competencies, in addition to the exceptional protein production facilities at NTU, make this an ideal group for undertaking such a broad-reaching comparative study.

This study also demonstrates the growing interest in fragment-based lead design (FBLD) as a means of accelerating many drug design programmes by complementing more traditional high-throughput or low-content assay screening methods. The Maybridge Ro3 500 Fragment Library, selected from the original Maybridge “Rule-of-Three” (Ro3) compliant set, is designed to be a convenient, cost-effective entry point to fragment screening.

Maybridge is part of Thermo Fisher Scientific, the world leader in serving science.

About Maybridge
Maybridge, part of Thermo Fisher Scientific, is well known for providing highly innovative drug-like molecules and screening compounds for drug discovery and development. With products available for both lab and development scale, they specialize in producing new heterocyclic and phenyl ring-based chemical building blocks, including a unique and expanding range of reactive intermediates. For more information about Maybridge brand products visit our website or call +44 18 40 77 05 67.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Alto Marketing Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Maybridge Fragments Selected by Nordlund Centre

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Leigh Dilley - Alto-Marketing.com 
+44(0)14 8955 7672 sarahp[.]alto-marketing.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Alto Marketing Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Alto Marketing Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)